Royalty Report: Drugs, Vaccine, Disease – Collection: 253954

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 15

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 15

Primary Industries

  • Drugs
  • Vaccine
  • Disease
  • Therapeutic
  • Cancer
  • HIV / AIDs
  • Delivery
  • Drug Discovery
  • Diagnostic
  • Pharmaceuticals
  • Immune
  • cell therapy
  • Herpes
  • Respiratory

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 253954

License Grant
The Parties agree to jointly research and develop Candidate Antigens and Licensed Products under a research program in accordance with the initial research plan.

For the Licenses for Collaboration Patents the Australian Licensors grants a nonexclusive, worldwide license, with the right to sublicense, under any Collaboration Patents that are owned solely by Licensor.

For the License for Licensed Products the Licensor grants to an exclusive license under the Licensed Subject Matter to develop, make, have made, use, offer to sell, sell, have sold and import Licensed Products within the Licensed Territory for use within the Licensed Field.

License Property
Licensed Product means a Vaccine Product that is covered by or made using Licensed Subject Matter and contains a Target Antigen related to a Target Disease.

Virus-like particles (VLPs) in their second-generation application are constructs that can be engineered to carry foreign antigens on their surface and mimic viruses in their ability to stimulate strong immune responses, in this case against foreign antigens.

Field of Use
The agreement is to collaborate in the discovery and development of vaccines against certain disease targets.  The Licensed Field means the development and commercialization of Vaccine Products for human therapeutic and prophylactic use.

The research and development (R&D) partnership focused on the use of Select Vaccines’ virus-like particles (VLPs) as a platform technology for the development of viral vaccines.  The R&D efforts will initially target the development of vaccines against influenza including both epidemic and pandemic forms of vaccine, with the opportunity to expand the collaboration to other disease targets.

IPSCIO Record ID: 4244

License Grant
The Licensor entered into a License Agreement with the Korean Licensee, to develop, manufacture and commercialize influenza vaccines using the Licensee's proprietary VLP technology.
License Property
The Licensor is a clinical-stage biopharmaceutical company focused on developing novel and effective recombinant vaccines. These vaccines leverage the Licensor's platform technology coupled with a single-use bioprocessing production system to develop virus-like particle (VLP) vaccines, as well as recombinant nanoparticle vaccines.

VLPs are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. The Company’s VLPs resemble the virus they were engineered to mimic, but lack the genetic material to replicate the virus and its single-use bioprocessing production technology uses insect cells rather than chicken eggs or mammalian cells.

The Licensor’s current product targets include VLP vaccines against seasonal and pandemic (including H5N1) influenza and a recombinant nanoparticle vaccine against Respiratory Syncytial Virus (RSV).

The upfront payment has been deferred and will be recognized as revenue when certain obligations in the agreement are satisfied.

Field of Use
At its own cost, the Licensee is responsible for funding its clinical development of the influenza VLP vaccines and completing a manufacturing facility in South Korea.

IPSCIO Record ID: 233439

License Grant
The Swiss Licensor grants a non-exclusive license under the adr-HBsAg Technology, with the right to sublicense, to research, develop, manufacture, have manufactured, market, distribute, import, use, offer for sale and sell Vaccines in the Territories for use solely in the Disease Field. Such license grant does not permit the transfer by Licensee to any third party of adr-HBsAg other than as part of assembled
Vaccines, including, without limitation, transfer of Vaccines to third parties for preclinical testing, toxicology, or clinical trials, without the prior written approval of Berna, such approval not to be unreasonably withheld.  The license granted is specific to the Disease Field.

Licensor grants the right to sublicense the right to research, develop, manufacture, have manufactured, market, distribute, import, use, offer for sale and sell Vaccines in the Territories under the adr-HBsAg Technology in the Disease Field.

License Property
adr-HBsAg shall mean the hepatitis B surface antigen of the subtype adr produced with the Hansenula polymorpha Expression System.

Therapeutic Vaccine shall mean a therapeutic hepatitis B vaccine developed by Licensee or its sublicensee and comprised of an ISS and adr-HBsAg, and that potentially utilises additional delivery or adjuvant technology, in pharmaceutical dosage forms suitable for human use.

Prophylactic Vaccine shall mean a prophylactic Hepatitis B vaccine developed by Licensee or its sublicensee and comprised of an ISS and adr-HBsAg, and that potentially utilizes additional delivery or adjuvant technology, in pharmaceutical dosage forms suitable for human use.

Field of Use
Disease Field shall mean the field of inducing an active, long term prophylactic response or therapeutic immune response against Hepatitis B, including chronic status, in humans.

IPSCIO Record ID: 253968

License Grant
University grants an exclusive, worldwide license, with the right to sublicense through multiple tiers, under the Patent Rights to develop, make, have made, use, and sell Licensed Products in the Field.
License Property
The licensed property includes any patents and patent applications that cover inventions disclosed in University invention disclosure UMMC05-46 entitled Virus-Like Particles as Vaccines for Paramyxovirus, including without limitation those applications having serial numbers 60/706,126; 11/497,888, and PCT filing.
Field of Use
Field means the diagnosis, prevention and/or treatment of any diseases and conditions in humans.

IPSCIO Record ID: 233458

License Grant
This amendment updates the grant, royalties, patents, and products.

The grant is replaced in its entirety with
The University grants to Licensee exclusive licenses under Patent Rights to make, use, sell, offer for sale, and import Patent Products and Vaccine Adjuvant Product and to practice the Patent Method. Licensee is expressly prohibited from selling a Derived Product or Vaccine Adjuvant Product to any third party, except that Licensee may sell a Vaccine Adjuvant Product to the Third Party.

The University also grants to Licensee the right to issue sublicenses to third parties to make, use, sell, offer for sale, and import Patent Products and practice the Patent Method, provided Licensee retains current exclusive rights under this Agreement.

The University also grants to Licensee the right to issue sublicenses to the Third Party to make, use, sell, offer for sale, and import Vaccine Adjuvant product and practice the Patent Method, provided Licensee retains current exclusive rights under this Agreement.

License Property
With this amendment
The patents include Biologically Active Composition Having A Nanocrystalline Core; Human Immunodeficiency Virus Decoy; and, Targeted Transfection Nanoparticles.

The Drug Delivery Product means a Licensed Product, which would, were it used or sold in the United States, require marketing approval by an appropriate regulatory agency for the use in pharmaceutical preparations to facilitate the therapeutic delivery of drugs in humans.

Vaccine Adjuvant Product means a Licensed Product that, when added as part of a Vaccine Product, improves the immune response so that less of a Vaccine Product is needed to produce more antibodies.

Vaccine Product means a Licensed Product, which would, were it used or sold in the United States, require marketing approval by an appropriate regulatory agency for any preparation containing a suspension of dead, attenuated, or otherwise modified microorganisms, e.g. viruses, bacteria, or rickettsiae, or parts thereof, that is used to produce an immunity against a disease in humans or other animals by stimulating the production of antibodies.

Derived Product means any product that is made by using a composition of matter claimed under Patent Rights or by practicing the Patent Method to make a final product regardless of the number of steps in the process or the number and types of compositions of matter, e.g., intermediate compounds, that are involved in making the final product. A Derived Product also means any product that is made by using a composition of matter claimed under Patent Rights whether or not that composition of matter is directly incorporated or a part of the final product.

Field of Use
Licensed Products means
– a kit, composition of matter, material, product, or Derived Product;
– a kit, composition of matter, material, product, or Derived Product to be used in a manner requiring the performance of the Patent Method; or
– a kit, composition of matter, material, product, or Derived Product produced by the Patent Method;

The Excluded Field means any field other than a Vaccine Product, Drug Delivery Product, and Vaccine Adjuvant Product.

Patents are in fields of use initially pertaining to (1) vaccine adjuvants; (2) vaccine constructs or combinations for use in immunization against herpes virus; (3) drug delivery systems; and (4) red blood cell surrogates.

IPSCIO Record ID: 275977

License Grant
The Licensor and Licensee of Denmark are working and cooperating with each other to conduct a joint program for the discovery and development of a vaccine.

The Research and Development Program will involve the systematic design and development of the Program Vaccine for use in the Field. The scope and goals of the Research and Development Program are subject to modification.

Licensor grants the Licensee of Denmark a worldwide, nonexclusive, non sublicensable and nontransferable license during the Research Term to practice the Licensor Background Technology, the Licensor Patent Rights and the Joint Patent Rights, solely in connection with activities to be performed by Licensor under the Research and Development Program.

Licensor grants a worldwide, non-exclusive and nontransferable license, with rights to sublicense, under the Licensor Background Technology, the Licensor. Patent Rights and the Joint Patent Rights, to make, have made, use, sell, offer for sale and import Licensee-Combined Vaccines or the Program Vaccines.

License Property
The licensed property includes proprietary Modified Vaccinia Ankara MVA technology to design vaccines.  Also developed vaccine products including those based on viral vectors, and T-cell epitope.
Field of Use
The Field shall mean any use of a vaccine product for the treatment or prevention of HIV in humans.

IPSCIO Record ID: 371191

License Grant
The Company holds an exclusive, worldwide license from the Licensor, a British university technology transfer and consultancy company, to certain specified patent rights and biological materials relating to the use of epitopes of limited variability and virus-like particle products and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for influenza. The Company is obligated to use its best efforts to develop and market Licensed Products in accordance with its development plan.
License Property
The patent, United States Patent No. 11,123,442, includes claims directed to specific compositions of polypeptides, or epitopes of limited variability, and methods of treating influenza infection with the compositions.

Epitopes or protein of antigens which can be utilized to develop singular or multi-targeted vaccines. Epitopes can simply be fused to the end of the S domain via flexible linker through recombinant DNA technology.  Identified epitopes of limited variability in H1 influenza that have circulated throughout history (since 1918) and make ideal vaccine targets and have completed similar analysis of H3 and Flu B strains for similar epitopes which will be used to produce our lead vaccine candidate BWV-101 as a universal vaccine for influenza infection.   Due to the cross-reactive nature of the H1 epitopes in pre-pandemic H1 influenza A, companies are pursuing the development of a stand-alone H1 vaccine (BWV-102). These epitopes are able to be formulated into a vaccine candidate using the VLP platform technologies and may be evaluated using other vaccine technologies through partnerships in order to accelerate development of potential vaccines or to explore adjunct therapies.

Field of Use
The Company is currently developing a universal influenza vaccine and an H1N1 vaccine candidate that both utilize the epitopes of limited variability that are covered in the patent.

Field of use is for the treatment of influenza.

IPSCIO Record ID: 257492

License Grant
Pursuant to the Agreement, Licensee obtained an exclusive license under Licensor patent rights and know-how to develop, make, have made, use and sell Licensed Products in the Territory.

With this amendment the parties wish to amend the Agreement to provide for the reversion of rights to Licensor under the Licensor patent rights and know-how for Influenza vaccine, HPV vaccine and HSV vaccine.

As of the Amendment Effective Date, the license granted to Licensee, and the rights and obligations of Licensee and Licensor arising therefrom, shall no longer apply to Influenza vaccine, HPV Vaccine and HSV Vaccine, and these vaccines shall no longer be deemed to be Licensed Products under the Agreement.

Hereby amended Licensor grants to Licensee an exclusive license, even as to Licensor, under Licensor know-how and patent rights to develop, make, have made, use and sell Licensed products in the Territory with the right to grant sub licenses to Affiliates of Licensee and those persons or entities through whom Licensee, in the normal course of its business collaborates in the manufacture and sale of its products; provided however, that nothing in this Agreement shall prohibit Licensor from utilizing the Licensor know-how and/or patent rights, exclusive of Licensee know-how, to develop, make, have made, use and sell, either by itself or with one or more third parties, products for the treatment of infectious diseases provided, further, notwithstanding the preceding proviso, that Licensor shall not have any right to develop, make, have made, use, or sell, either by itself or with one or more third parties, Treatment Vaccines.

Licensor grants an option to obtain a license under theLicensor patent rights and know-how to make, have made, use, sell, offer to sell and import Cancer Vaccines in the Territory for up to three (3) Cancer targets. Such Cancer target license shall be exclusive, even as to Licensor, for each Cancer Target so licensed, and shall be sublicenseable by Licensee pursuant to the terms applicable to Licensed Products.

License Property
This amendment includes Amended Definitions Relating to Cancer targets, and, Licensed Product means a bulk or finished AIDS Vaccine, or other vaccine for the prevention of human infectious disease if licensed hereunder, which utilizes the Technology or technology which is developed by Licensor during and as a result of the research collaboration program; and upon the exercise of an Option for a Cancer vaccine, such bulk or finished Cancer vaccine for the prevention of Cancer Indications, provided, however, that if any vaccine is also capable of being used for treatment of the same human infectious disease or Cancer indication, then such therapeutic use of such vaccine shall also be considered a Licensed Product for purposes of the license being granted by Licensor to Licensee under this Agreement; and Treatment vaccines.

Treatment vaccines means a bulk or finished vaccine.

Field of Use
The field of use is for the treatment of Human Immunodeficiency Virus (HIV-1) and/or diseases caused by infection with HIV-1 in humans;  Hepatitis Virus (HBV) and or diseases caused by infection with HBV in humans; and Cancer vaccines for the treatment, but not prevention or prevention and treatment, of Cancer Indications.

IPSCIO Record ID: 345562

License Grant
English Licensor granted a nonexclusive license to Licensee to produce and characterize potential product candidates using the Company’s viral vector technology and to provide research services to Licensee during the research term which commenced on June 2019 through the end of 66 months and for up to six vaccine products based on antigens discovered via Licensee’s proprietary platform.
License Property
Viral vector technology is known as ChAdOx1 and ChAdOx2.  This platform comprises several components that, when combined, allow the developed product candidates designed to induce high and durable levels of antigen-specific T cells and B cells, to prevent and treat infectious diseases and cancer.

ChAdOx1 and ChAdOx2 are modified simian adenoviral vectors which deliver target antigens into cells to generate a specific immune response. These viruses were originally isolated from chimpanzees to avoid pre-existing immunity issues affecting the use of human adenovirus vectors.

Field of Use
Field of use is for the immunotherapy and vaccine fields.

IPSCIO Record ID: 368651

License Grant
Licensor grants a worldwide, exclusive license to Licensor Patent Rights and Know-How to make, have made, use, import, offer to sell, and sell Product using Licensed Compound supplied by Licensor, or supplied by a third party, for use in the Field.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor, through its Drug Delivery Systems Division, has expertise and technology, with know-how and patents owned by Licensor, relating to toll-like receptor TLR 7 and/or 8 immune response modifier (IRM) compounds, formulations, conjugation, delivery, and manufacturing including proprietary IRM compounds such as resiquimod and others, that are useful as vaccine adjuvants.

The Compound is designated by Licensor as Resiquimod (R-848), S36212, 1-(4-aminobutoxy) -2-butyl-lH-imidazo (4,5-cl quinolin-4-amine and conjugates thereof.

Product shall mean any combination of a Licensee Antigen Presenting Cell or APC Targeting Technology vaccine with a Licensed Compound to be utilized as a Vaccine Adjuvant.

Vaccine Adjuvant shall mean a Licensed Compound which is used to induce, augment, fine-tune, enhance, or desensitize an antigen-specific immune response to an antigen contained in a vaccine or generated by a DNA vaccine for the therapeutic treatment of an existing disease or prophylactic use as protection against future disease, including desensitization to allergens. The antigen and the vaccine adjuvant may be admixed, delivered simultaneously, conjugated, or delivered separately, provided however, that the separate administration of the antigen and vaccine adjuvant is limited to the topical, dermal or mucosal or intradermal routes of administration and must be administered within 48 hours at substantially the same site and labeled as such by the applicable regulatory authority.

TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.

Field of Use
Licensor’s patented TLR immune response modifier compounds, which may be useful as vaccine adjuvants, will be used by Licensee to develop new vaccine products.  This license agreement provides a great opportunity to combine synergistic technologies designed to treat various cancers and infectious diseases.

The Field shall mean human prophylactic or therapeutic vaccination against any and all cancer disease states and selected infectious diseases.

This agreement focus is Cancer and the Infectious Diseases
– human immunodeficiency virus (HIV);
– human papillomavirus (HPV); and,
– hepatitis B virus (HBV).

IPSCIO Record ID: 319599

License Grant
Licensor, one of the nation’s leading research universities in topics such as health sciences, hereby grants to Licensee a limited, transferable (solely to Patriot Scientific or any purchaser of Licensee), exclusive license (referred to as Evaluation License) to evaluate the Materials for use in the Field of Use and to practice any method, process or procedure during the Evaluation Period solely for purposes of the Evaluation. The Evaluation License will terminate upon the expiration or termination of this Agreement, unless extended by mutual agreement. No other evaluation license will be granted in the Field of Use for the Evaluation Period.

Licensor hereby grants to Licensee the exclusive option to enter into a license agreement from Licensor for the commercial development, use, and sale of the Technology, products based on the Technology, patents, trade secrets, know-how, and other information related to the Technology;

License Property
Technology shall mean Materials or any intellectual property developed by Licensee from Materials including without limitation, all or any of the inventions and developments related thereto or arising out of any compositions, data, strains, patent applications, processes, techniques, contained therein and any physical embodiments thereof.

Materials shall mean the materials and/or intellectual property listed
– Licensor IDF Number 2013-2417 entitled “Non-Covalent Loading of Plant Picornavirus Particles” with US Patent Application US2015/0376578 A1 and EP Patent Application 14754692.3
– Licensor IDF Number 2015-2767 entitled “Cancer Immunotherapy using Virus Particles with US Patent Application US2018/0133304 A1 and associated foreign patent applications in Japan, China, Canada, Australia, and EP, US non-published patent application with patent serial number 16/612,214, and PCT Patent application with publication number WO 2018/208828 A1
– Licensor IDF Number 2017-3151 entitled “Melt Processed Viral Nanoparticle Constructs” with US Patent Application US2019/0350871 A1 and EP Patent Application 17868454.4

Patents shall mean any patent that issues or has issued to Licensor or patent application covering or consisting of the Technology and based on intellectual property in existence as of the Effective Date and any related patent or patent application that is a continuation, continuation-in-part, divisional, or reissue in the United States of America or any other country.

Field of Use
The technology is a novel platform technology using virus-like nanoparticles to treat and prevent cancer and infectious diseases in humans and for veterinary use.

The technology also has direct application as part of a vaccine platform, which has generated promising data in both cancer and infectious diseases, including COVID-19.
The researchers have collectively demonstrated that plant-derived, engineered VLP-based nanotechnologies stimulate a potent anti-tumor immune response in mouse models of metastatic melanoma, ovarian cancer, colon cancer, brain cancer and breast cancer, including companion dogs with metastatic melanoma. This data supports the potential to translate preclinical studies into veterinary applications, such as the treatment of cancer in companion animals, which has high relevance to human melanoma.
This immuno-oncology approach provides a personalized treatment approach by relieving the patient’s tumor-mediated immunosuppression and potentiating anti-tumor immunity against antigens expressed by their own tumor.

The vaccine platform is a natural extension of the immune-stimulating properties of the VLP, combined with directing the response to pre-defined targets. Instead of being a personal vaccine, the modular approach of linking disease specific targets to the VLP allows the potential to rapidly develop countermeasures for pandemics such as COVID-19.

Field of Use shall mean all therapeutic, diagnostic, vaccine and preventive uses of Technology for both veterinary and human applications. Final field of use, including specific indications, which may be narrower than the Field of Use, will be defined in any commercial use license. Said commercial use license will necessarily incorporate developmental, regulatory, and commercial distribution/sales milestones for each product that incorporates any Technology in the Field of Use. For clarification purposes, Technology and Materials shall not be used in or on humans during the Evaluation Period unless Licensee consults with Licensor regarding appropriate, and possibly expanded, indemnification and insurance requirements and receives Licensor’s written authorization to do so. Such authorization will be in Licensor’s sole discretion.

IPSCIO Record ID: 273437

License Grant
The Licensor of Denmark and the Licensee are working and cooperating with each other to conduct a joint program for the discovery and development of a vaccine.

The Research and Development Program will involve the systematic design and development of the Program Vaccine for use in the Field. The scope and goals of the Research and Development Program are subject to modification.

Licensor grants a worldwide, nonexclusive, nonsublicensable and nontransferable license during the Research Term to practice the Licensor Background Technology, the Licensor Patent Rights and the Joint Patent Rights, solely in connection with activities to be performed by Licensee under the Research and Development Program.

Subject to the exercise by Licensee of the Combination Option or Option, Licensor grants to a worldwide, non-exclusive and non-transferable license, with rights to sublicense, under the Licensor Background Technology, the Licensor Patent Rights and the Joint Patent Rights, to use, sell, offer for sale and import Combined Vaccine or the Program Vaccine during the Term.

License Property
The licensed property includes proprietary Modified Vaccinia Ankara MVA technology to design vaccines.  Also developed vaccine products including those based on viral vectors, and T-cell epitope.
Field of Use
The Field shall mean any use of a vaccine product for the treatment or prevention of HIV in humans.

IPSCIO Record ID: 308733

License Grant
This collaboration is for the Development of vaccine product candidates which incorporate one or more Licensee Antigens and the Licensed Adjuvant.

For the Exclusive License, the Licensor of Sweden grants an exclusive license, with the right to grant sublicense, under the Licensed Technology to import, make, have made, use, sell, offer for sale and otherwise exploit Licensed Products in the Exclusive Field in the Territory and otherwise exploit the Licensed Know-How in connection therewith.

For the Time-Limited Exclusive License, Licensor grants an exclusive, limited in time license, with the right to grant sublicenses, under the Licensed Technology to import, make, have made, use, sell, offer for sale and otherwise exploit Licensed Products in the Time-Limited Exclusive Field in the Territory and otherwise exploit the Licensed Know-How in connection therewith.

For the Non-Exclusive License, Licensor grants a nonexclusive  license, with the right to grant sublicenses, under the Licensed Technology to import, make, have made, use, sell, offer for sale and otherwise exploit Licensed Products in the Non-Exclusive Field in the Territory and otherwise exploit the Licensed Know-How in connection therewith; provided, however, that with respect to the Joint Technology.

License Property
Licensor owns or otherwise controls certain intellectual property relating to the Licensed Adjuvant.

Licensee Antigen means any antigen (a) owned or otherwise Controlled by Licensee and (b) believed to trigger an immune response causing the production of antibodies and/or cytokine or T-cell responses in humans as a defense against or treatment for a Disease Field.

Licensed Adjuvant means an adjuvant Controlled by Licensor which incorporates or is developed from Matrix-A, Matrix-C and/or Matrix-M technology.

Licensed Product means any vaccine product containing both the Licensed Adjuvant and one or more Licensee Antigens; provided, however a Licensed Product may include a combination vaccine product for two or more Disease Fields but not a combination vaccine product for a Disease Field and a field that is not a Disease Field.

Matrix-A means a component of the Matrix M adjuvant that is produced by mixing together HPLC-purified fraction A from Quillaja saponin bark, cholesterol and phosphatidyl choline to form Iscom particles.

Matrix-C means a component of the Matrix M adjuvant that is produced by mixing together HPLC-purified fraction C from Quillaja saponin bark, cholesterol and phosphatidyl choline to form Iscom particles.

Matrix-M means a suspension of Matrix A and Matrix C particles that are combined in varying ratios of Matrix A to Matrix C.

Field of Use
The Field means the Exclusive Field, the Time-Limited Exclusive Field, and the NonExclusive Field.   The Exclusive Disease Fields shall be herpes simplex virus (HSV) and Chlamydia.  The Selection of Time-Limited Exclusive Field is until twelve (12) months after the Effective Date, and Licensee shall have the right, at any time, to appoint up to three (3) Time-Limited Exclusive Disease Fields.  The Selection of Non-Exclusive Fields is until twenty-four (24) months after the Effective Date, and Licensee shall have the right, at any time, to appoint up to five (5) NonExclusive Disease Fields.

The agreement grants Licensee license to two patent families, to import, make, have made, use, sell, offer for sale and otherwise exploit licensed vaccine products containing an adjuvant which incorporates or is developed from Matrix-A, Matrix-C and/or Matrix-M technology, in the fields of HSV and chlamydia, and the time-limited exclusive fields of Neisseria gonorrhoeae, cytomegalovirus, or CMV, and Mycobacterium tuberculosis.

Licensee is a clinical stage biotechnology company that discovers and develops novel vaccines to address infectious diseases for which no vaccine or vaccines with limited effectiveness exist today, using a proprietary discovery platform, ATLAS, to rapidly design vaccines that act through T cell (or cellular) immune responses, in contrast to approved vaccines, which are designed to act primarily through B cell (or antibody) immune responses. Licensee is also developing a second T cell vaccine candidate, GEN-004 for pneumococcus, a leading cause of infectious disease mortality worldwide.

IPSCIO Record ID: 279292

License Grant
For the Licensed Intellectual Property, Licensor grants the exclusive, even as to Licensor, a worldwide, nontransferable right and license, with the right to grant sublicenses, under the Licensed Intellectual Property, to use, have used, sell, have sold, offer to sell, import, have imported, make and have made, and otherwise research, Develop, Commercialize or manufacture any Licensed Vaccine and/or Licensed Product, during the Term, in the Territory in the Field.

For the Trademarks for Licensed Products. To the extent that Licensor owns any Trademark(s) that pertain specifically to a Licensed Vaccine or Licensed Product, Licensor grants an exclusive right and license, with the right to grant sublicenses to Trademark(s) Controlled by Licensor solely for use with respect to such Licensed Vaccine or Licensed Product, as the case may be.

License Property
Licensor has expertise in drug discovery, development, and manufacturing of yeast-based immunotherapeutics known as Tarmogen® products.

Licensor has rights under certain patent rights and know-how rights relating to Tarmogens.

Licensed Product means any product in final form that contains a Licensed Vaccine as a therapeutically or prophylactically active ingredient.

Combination Product means any product sold in a particular country that contains a Licensed Vaccine in combination with one (1) or more other therapeutically active ingredients or drug delivery technology, devices, equipment or other components, as applicable, or formulated or packaged separately but sold together for a single price.

Field of Use
The collaboration is for the prevention and/or treatment of hepatitis B virus infection and its sequelae.  The goal of the research collaboration is to create and develop therapeutic vaccine products that have specific HBV DNA antigens cloned into S. cerevisiae (a species of yeast).

The Field means, any and all human diseases and conditions, except the treatment of any malignancy; provided, however, that Field shall include [the treatment, palliation, diagnosis and/or prevention of hepatitis that may result in the prevention and/or reduction in frequency and incidence of any and all sequelae of hepatitis infection, including the prevention and/or reduction in the frequency and incidence of hepatocellular carcinoma in patients who have co-existing hepatocellular carcinoma.

IPSCIO Record ID: 277105

License Grant
For outside the licensed field, Licensor grants a worldwide, non-exclusive, and sublicenseable right and license to practice Licensors rights in Joint Collaboration Patent Rights to make, have made, import, promote, market, distribute or sell Licensee Products outside the Licensed Field.

This agreement contains both exclusive and non-exclusive grants between the parties.

License Property
The Patent Rights and Know-How are pertaining to the PADRE® Technology.

Licensed Product shall mean a therapeutic or prophylactic vaccine the manufacture. use or sale of which, but for any license granted to Licensee herein, would infringe a Valid Claim of one or more Licensor Patent Rights or one or more Collaboration Patent Rights, or was developed or manufactured using Licensor Know-How.

PADRE® Technology shall mean a family of immunostimulatory molecules which when combined with cytotoxic T cell epitopes increase the magnitude and duration of the immune response.

Field of Use
Licensed Field shall mean the research, development and commercialization of Licensed Products for treating or preventing diseases associated with the following viruses HPV. HBV and HCV.  HBV shall mean Hepatitis B Virus.  HCV shall mean Hepatitis C Virus.  HPV shall mean Human Papilloma Virus.  First HPV Indication shall mean treatment or prevention of cervical dysplasias and neoplasia.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.